Supernus Pharmaceuticals, Inc. (Supernus) operates as a biopharmaceutical company focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
The company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company is...
Supernus Pharmaceuticals, Inc. (Supernus) operates as a biopharmaceutical company focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
The company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company is developing a broad range of novel CNS product candidates, including new potential treatments for epilepsy, depression, and other CNS disorders.
Strategy
The key elements of the company's strategy are to drive growth and profitability; advance product candidates toward commercialization; continue to grow its pipeline; and target strategic business development opportunities.
Commercial Products
The company's commercial products, including those sold by or through its subsidiaries, include:
Qelbree
Qelbree (viloxazine extended-release capsules) is a novel non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older. On April 2, 2021, the FDA approved Qelbree for the treatment of ADHD in pediatric patients 6 to 17 years of age. In May 2021, the company launched Qelbree for pediatric patients in the U.S. On April 29, 2022, the FDA approved Qelbree for the treatment of ADHD in adult patients. The company launched Qelbree for adult patients in May 2022. In January 2025, the FDA approved an expanded label update for Qelbree to include new data on the pharmacodynamics and use in breastfeeding mothers.
GOCOVRI
GOCOVRI (amantadine) extended-release capsules is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa/carbidopa in patients with PD experiencing ‘off’ episodes.
GOCOVRI was approved by the FDA in August 2017 for the treatment of dyskinesia and in February 2021 as an adjunctive treatment for ‘off’ episodes. The February 2021 update to the label indication makes GOCOVRI the only medicine clinically proven and approved to reduce both ‘off’ episodes and dyskinesia in PD patients taking a levodopa-based medication, resulting in a clinically meaningful increase in good ‘on’ time without the need for a ‘trade-off’ when managing these motor complications.
Oxtellar XR
Oxtellar XR is indicated for the treatment of partial-onset seizure in adults and children 6 years of age and older. Oxtellar XR is the first once-daily extended-release oxcarbazepine product indicated for the treatment of epilepsy in the U.S. market. In 2013, the company launched Oxtellar XR for adjunctive therapy in the treatment of partial-onset seizures in adults and children 6 to 17 years of age. In January 2019, the company launched Oxtellar XR for monotherapy treatment of partial onset epilepsy seizures in adults and children 6 to 17 years of age.
APOKYN
APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility or off episodes (end-of-dose wearing off" and unpredictable on-off episodes) in patients with advanced PD. APOKYN's adjustable dose subcutaneous injection pen is designed to quickly and reliably reverse the effects of oral levodopa wearing off in patients with inadequately controlled PD.
Trokendi XR
Trokendi XR is indicated for epilepsy: initial monotherapy for the treatment of partial-onset and primary generalized tonic-clonic (PGTC) seizure in patients 6 years of age and older (1.1); adjunctive therapy for the treatment of partial-onset, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut Syndrome in patients 6 years of age and older (1.2); and for preventive treatment of migraine in patients 12 years of age and older. Trokendi XR is the first once-daily extended-release topiramate product indicated for the treatment of epilepsy and the prophylaxis of migraine headaches in adults and adolescents in the U.S. market.
XADAGO
XADAGO (safinamide) is a once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD who are experiencing off episodes. XADAGO is a monoamine oxidase B (MAO-B) inhibitor that works by blocking the catabolism of dopamine, which is believed to result in an increase in dopamine levels, and therefore a subsequent increase in dopaminergic activity in the brain. XADAGO was approved by the FDA in March 2017.
The company has entered into settlement agreements with third parties permitting the sale of a generic version of XADAGO beginning in December 2027, or sooner under certain conditions.
MYOBLOC
MYOBLOC (rimabotulinumtoxinB) is a product indicated for the treatment of cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia in adults and treatment of chronic sialorrhea in adults. MYOBLOC is the only Type B toxin available on the market. MYOBLOC injections must be administered by a physician.
MYOBLOC was approved by the FDA in August 2019 for the treatment of chronic sialorrhea in adults and in December 2000 for the treatment of adults with cervical dystonia.
ONAPGOTM
ONAPGO (apomorphine hydrochloride) injection is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. ONAPGO was approved by the FDA in February 2025 and received an Orphan Drug Designation. ONAPGO will be launched in the second quarter of 2025.
Research and Development
The company's research and development expenses included $108.8 million in 2024.
The company also engages in a variety of research and development efforts, including the development of a pipeline of novel CNS product candidates for the treatment of various CNS conditions. The company has devoted, and continues to devote, significant resources to research and development activities.
ONAPGO (formerly SPN-830)
ONAPGO (apomorphine hydrochloride) injection is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. ONAPGO was approved by the FDA in February 2025 and received an Orphan Drug Designation. ONAPGO will be launched in the second quarter of 2025.
The approval of ONAPGO is based on results from a Phase 3, twelve-week, multicenter, parallel-group, double-blind, randomized, placebo-controlled study (N=107) evaluating the efficacy and safety of ONAPGO. The primary efficacy endpoint was the mean change in total daily ‘off’ time assessed from baseline to the end of the twelve-week treatment period based on patient diaries. The key secondary endpoints were the mean change in daily GOOD ON time, which was defined as on time without troublesome dyskinesia, and Patient Global Impression of Change (PGIC).
During the Phase 3 study, ONAPGO significantly reduced the amount of daily ‘off’ time at twelve weeks from baseline (p=0.0114), with ONAPGO-treated patients (n=53) experiencing a 2.6-hour reduction compared to placebo (n=51) with 0.9 hours. The reduction in daily ‘off’" time was accompanied by a similar significant increase in daily GOOD on time (2.8 hours for ONAPGO-treated patients compared to 1.1 hours for the placebo group; p=0.0188). In addition, numerically greater improvements in daily ‘off’ time and daily GOOD on time were seen as early as the first week of treatment and were maintained throughout all measured timepoints. Additionally, ONAPGO-treated patients more frequently reported improvement in their state of general health compared with placebo-treated patients (PGIC: 79% vs. 24%; p<0.0001). The most common adverse events (=10% incidence) were infusion-site nodule, nausea, somnolence, infusion-site erythema, dyskinesia, headache, and insomnia.
SPN-817 (huperzine A)
SPN-817 represents a novel MOA for an anticonvulsant. SPN-817 is a novel synthetic form of huperzine A, whose MOA includes potent acetylcholinesterase inhibition, with pharmacological activities in CNS conditions such as epilepsy. The development will initially focus on the drug's anticonvulsant activity, which has been shown in preclinical models to be effective for the treatment of partial seizures and Dravet Syndrome. SPN-817 has received Orphan Drug Designation for both Dravet Syndrome and Lennox-Gastaut Syndrome from the FDA.
The company focuses on completing and optimizing the synthesis process of the synthetic drug, as well as developing a novel dosage form. Given the potency of SPN-817 (huperzine A), a novel extended-release oral dosage form is critical to the success of this program because initial studies with the immediate-release formulations of non-synthetic SPN-817 (huperzine A) have shown serious dose-limiting, side effects.
The company is conducting an open-label Phase 2a clinical study of SPN-817 in patients with treatment-resistant seizures. The first part of this study (Stage A) has completed dosing in the titration and maintenance periods. The company has completed enrollment of Stage A and announced, in November 2024, the topline data from all subjects with focal seizures who received the 3mg and 4mg twice daily doses, completed the maintenance period (n=10), and enrolled in the post-maintenance extension period (n=6).
SPN-820 (NV-5138)
SPN-820 is a first-in-class, orally active small molecule that activates the brain mechanistic target of rapamycin complex 1 (mTORC1), a gatekeeper of cellular metabolism and renewal. SPN-820 binds to and modulates sestrin, which senses amino acid availability in the brain, a potent natural activator of mTORC1.
Depression is associated with synapse loss and reduced synaptic plasticity in key brain regions, including the prefrontal cortex, and increasing mTORC1-mediated synaptic plasticity is a promising avenue to treat depression and associated symptoms. SPN-820 selectively binds to intracellular sestrin proteins and subsequently engages a cascade of multi-protein complexes, enhancing mTORC1 signaling. A single administration of SPN-820 rapidly (within one hour) and transiently (within seven hours) enhances intracellular mTORC1 signaling in the prefrontal cortex of animals, restores levels of synaptic proteins, and reduces depressive-like behaviors in a brain-derived neurotrophic factor (BDNF)-dependent manner. The rapid and transient enhancement of mTORC1 signaling in the prefrontal cortex is required for anti-depressant effects in preclinical animal models. The intracellular mechanism of SPN-820, as well as the lack of binding to cell surface receptors, suggests the potential for a differentiated safety profile.
A Phase 1 trial demonstrated early proof of concept in which a single dose of SPN-820 showed a rapid and sustained improvement in core symptoms, with favorable safety and tolerability in patients with treatment resistant depression.
The company completed a Phase 2a multi-center open label study in 40 subjects with Major Depressive Disorder (MDD) in the fourth quarter of 2024. The data were based on 40 enrolled subjects, of which 38 completed the ten-day treatment period. The primary objective of the study was to assess efficacy in MDD, as well as the onset of efficacy. The Phase 2a study demonstrated a rapid and substantial decrease in depressive symptoms, along with an 80% decrease in suicidal ideation. SPN-820 was well-tolerated during the study, with few adverse events reported by the subjects. In addition, the data demonstrated a rapid Montgomery–Asberg Depression Rating Scale (MADRS) response rate (=50% reduction) and remission (MADRS =10), reaching 50.0% and 35.0% of subjects, respectively, at 4 hours, with additional improvement to 84.2% and 63.2% of participants by Day 10.
In February 2025, the company reported topline results from the Phase 2b study of SPN-820. The Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the MADRS total score to Week 4 (SPN-820 [LS mean ± Standard Error]: -12.3 ± 0.96 vs. placebo: -11.9 ± 0.96; p = not significant). There was no treatment difference between SPN-820 and placebo in the change from baseline to Week 4 for the secondary endpoints. The safety profile of SPN-820 was consistent with previous clinical trials, showing few adverse events.
The Phase 2b study was a multi-center randomized double-blind placebo-controlled trial of SPN-820 in adults with treatment-resistant depression. The study examined the efficacy and safety of SPN-820 over a course of four weeks of treatment, followed by a week of blinded placebo washout in approximately 250 patients from around 40 clinical sites. The primary outcome measure was the change from baseline to the end of the treatment period on the MADRS Total Score.
SPN-443 – Novel stimulant for the treatment of ADHD/CNS
The company completed a Phase 1 single dose study in healthy adults in 2024, following submission of an Investigational New Drug Application. The study was a first-in-human, pilot pharmacokinetic study of two oral formulations of SPN-443 in healthy adults. The primary objective of the study was to assess safety and tolerability. This molecule, along with its major metabolites, is an inhibitor of norepinephrine, dopamine, and serotonin, also known as a triple reuptake inhibitor. Both formulations of SPN-443 showed adequate bioavailability and were well tolerated.
Sales and Marketing
The company markets its key products through its own sales forces in the U.S. and seeks strategic collaborations with other pharmaceutical companies to commercialize its products outside of the U.S. The company has a commercial sales and marketing organization in the U.S. to support sales of its commercial products.
One sales force focuses on serving movement disorder specialists and other specialized healthcare providers in the U.S. in the Parkinson's area.
The second sales force focuses on serving psychiatrists, pediatricians, primary care physicians and other health professionals in the ADHD area.
Customers
The majority of the company's product sales are to pharmaceutical wholesalers, specialty pharmacies, and distributors who, in turn, sell its products to pharmacies, hospitals, and other customers, including federal and state entities. The majority of sales of Qelbree, Oxtellar XR, Trokendi XR, and XADAGO are made to wholesalers and distributors. In addition, MYOBLOC is available for direct purchase by physicians and hospitals. The majority of sales of GOCOVRI and APOKYN are made to specialty pharmacies.
Each of the company's three major customers, Cencora, Inc., Cardinal Health, Inc., and McKesson Corporation, individually accounted for more than 20% of its total product revenue in 2024 and collectively accounted for more than 77% of its total product revenue in 2024.
Manufacturing
The company has agreements with CMOs headquartered in North America, including Patheon Pharmaceuticals, Inc. (a subsidiary of Thermo Fisher Scientific Inc.), Packaging Coordinators, Inc., Aphena Pharma Solutions, and Catalent Pharma Solutions, as well as in Europe and Asia, for the manufacturing and packaging of some of its commercial products, including those of its subsidiaries, as well as for its pipeline product candidates. For Qelbree, Trokendi XR, GOCOVRI, and Oxtellar XR, the company currently relies on third-party CMOs for the manufacturing and packaging of final commercial products. The company relies on third-party CMOs in Asia for the manufacturing of bulk drug substance for Trokendi XR and Oxtellar XR and relies on a third-party CMO in Europe for the raw materials and manufacturing of Qelbree and GOCOVRI. With respect to GOCOVRI and Qelbree, the company has an additional manufacturer of bulk drug substance.
The company purchases APOKYN, ONAPGO, MYOBLOC, and XADAGO as finished goods. APOKYN is manufactured and packaged in Europe for the U.S. market and is supplied to the company by its licensing partner, Britannia. ONAPGO is manufactured in Europe, supplied to the company by Britannia, and packaged in the U.S. Britannia (a subsidiary of Stada Arzneimittel AG) also supplies injectable apomorphine to the European market under the brand name Apo-go. MYOBLOC is manufactured and packaged in Europe by Merz GmbH & Co. KGaA (Merz). XADAGO is manufactured and packaged in Europe by Zambon S.p.A. (Zambon).
Proprietary Technology Platforms
The company's key proprietary technology platforms include Microtrol, Solutrol, and EnSoTrol. These technologies have been utilized to create novel, customized product profiles designed to enhance efficacy, reduce the frequency of dosing to improve patient adherence, and improve tolerability. The company's technologies have been used to create ten commercial products, including its products: Qelbree, Trokendi XR, and Oxtellar XR; Adderall XR (developed for Shire, which has been acquired by Takeda Pharmaceutical Company); Intuniv (developed for Shire); Mydayis (developed for Shire); Orenitram (developed for United Therapeutics Corporation); and Namzaric (developed for Allergan plc).
The company also engages in generating and assessing New Chemical Entities (NCEs). These NCEs are generated by leveraging the company's expertise in structure function relationships in active molecules. The company's NCEs are being assessed in preclinical pharmacology models for CNS activity and are advancing towards Investigational New Drug application (IND) enabling toxicology studies to support potential future clinical investigation.
Intellectual Property and Exclusivity
Patent Portfolio
The company's commercial products, including those of its subsidiaries, covered by active patents include Trokendi XR, Oxtellar XR, Qelbree, GOCOVRI, Osmolex ER, and XADAGO. The company, or its subsidiaries, owns all the issued patents for Trokendi XR, Oxtellar XR, Qelbree, GOCOVRI, and Osmolex ER, as well as the pending U.S. patent applications for Qelbree and GOCOVRI. The company has a license from Zambon for the U.S. patents that cover XADAGO.
Qelbree
The company has three families of pending U.S. non-provisional and foreign counterpart patent applications for Qelbree. Patents, if issued, could expire from 2029 to 2035. The company has patents issued in the U.S., Canada, and certain countries in Europe covering a method of treating ADHD using viloxazine hydrochloride. In a second family, covering the novel synthesis process of the active ingredient, the company has patents issued in the U.S. as well as in certain foreign countries. In a third family, the company has four patents issued in the U.S. covering modified release formulations of viloxazine hydrochloride, three of which cover Qelbree. The company also has patents issued in certain foreign countries. The company owns all the issued patents and the pending patent applications.
GOCOVRI
The company's patent portfolio covering GOCOVRI includes 19 U.S. patents. The company has additional pending applications containing method and composition claims relating to the pharmacokinetic profile, dosing, and formulations of amantadine extended release. The issued patents expire through 2038. These patents and patent applications are owned by Adamas Operations and, as of the first quarter of 2022, are licensed to Supernus Pharmaceuticals, Inc.
Prior to the company's acquisition of Adamas, Adamas entered into settlement agreements with third parties, permitting the sale of a generic version of GOCOVRI (amantadine) extended-release capsules (including for any new indications approved under the GOCOVRI NDA) on or after June 4, 2029.
Oxtellar XR
The company's extended-release oxcarbazepine patent portfolio currently includes 14 U.S. patents, 11 of which cover Oxtellar XR. The 11 issued U.S. patents covering Oxtellar XR will expire no earlier than 2027. The company owns all of the issued patents and the pending U.S. patent applications. The company also owns additional foreign patents for extended-release oxcarbazepine.
The company entered into settlement and license agreements with third parties, permitting the sale of a generic version of Oxtellar XR beginning in September 2024.
Trokendi XR
The company currently has 10 U.S. patents that cover Trokendi XR. The company owns all the issued patents. The company also owns additional foreign patents for extended-release topiramate. The ten issued U.S. patents covering Trokendi XR will expire no earlier than 2027.
XADAGO
The patent portfolio covering XADAGO has 3 U.S. patents licensed from Zambon. These patents will expire from 2027 to 2031.
The company has entered into settlement agreements with third parties, permitting the sale of a generic version of XADAGO beginning in December 2027, or earlier under certain circumstances.
ONAPGO
In February 2025, ONAPGO received Orphan Drug Designation in the U.S. from the FDA. ONAPGO received seven years of U.S exclusivity from the time of approval by the FDA.
SPN-817 (huperzine A)
The company has one patent issued in the U.S., as well as in China, Mexico, and certain other foreign countries relating to extended-release formulations of huperzine. The company additionally has pending patent applications in the U.S. and certain foreign countries.
SPN-820 (NV-5138)
Under the terms of the April 2020 Development Agreement with Navitor Pharmaceuticals, Inc. (Navitor Inc.), the company has an exclusive option to license or acquire NV-5138 in all world territories, prior to the initiation of the Phase 3 clinical program. NV-5138 has multiple patents issued covering composition of matter, various methods of use, etc., in the U.S. and certain other foreign countries. The issued patents have expiration dates of 2036-2038 or beyond. There are additional pending patent applications in the U.S. and certain foreign countries.
Other Intellectual Property Rights
The company, including its subsidiaries, seeks trademark protection in the U.S. and internationally, where available and when appropriate. The company, along with its subsidiaries, has filed for trademark protection for several marks, which are used in connection with its pharmaceutical research and development collaborations, as well as with its products and those of its subsidiaries. The company or its subsidiaries are the owner/licensee of various U.S. federal trademark registrations and registration applications , including Supernus, Microtrol, Qelbree, GOCOVRI, Oxtellar XR, APOKYN, Trokendi XR, XADAGO, MYOBLOC, Osmolex ER, Namzaric, ONAPGO, and the registered Supernus Pharmaceuticals logo.
Collaborations and Licensing Arrangements
APOKYN and ONAPGO (apomorphine hydrochloride)
In January 2016, the company entered into an Amended and Restated Distribution, Development, Commercialization, and Supply Agreement with Britannia that grants it certain intellectual property and product rights in relation to APOKYN, including the right to use and market APOKYN in the United States (Territory). Additionally, under the agreement, Britannia retains certain intellectual property and product rights in relation to APOKYN, including the right to use and market APOKYN in the rest of the world, excluding the United States. Under the Agreement, Britannia has an obligation to supply the company with APOKYN for its marketing and sale of the product.
XADAGO
In February 2016, the company entered into a License and Distribution Agreement and a Supply Agreement with Zambon. Under the License and Distribution Agreement, the company is the exclusive distributor of XADAGO in the U.S. and is prohibited from selling or distributing in the U.S. certain products that compete with XADAGO. Additionally, Zambon is eligible to receive up to $30.0 million in future payments upon the achievement of sales-based milestones, which are based upon specified annual net product sales of XADAGO in the U.S. During the term of the License and Distribution Agreement, the company is also obligated to pay a royalty on net product sales of XADAGO in the U.S. In the event that XADAGO annual net sales exceed the specified U.S. annual net product sales thresholds, the royalty percentage increases and could go as high as the mid-teens.
MYOBLOC
In May 2004, the company entered into an asset purchase agreement with a third party, resulting in it owning the worldwide rights to MYOBLOC in exchange for paying a low double-digit royalty based on U.S. annual net sales of MYOBLOC. The company makes royalty payments to Elan Pharmaceuticals, LLC, a subsidiary of Perrigo Pharma International DAC. While the company currently has no intention of seeking approval in the U.S. for cosmetic use, if MYOBLOC is approved for such use, a milestone payment would be due, and the royalty rate will become subject to certain reductions based on cosmetic use net sales. The company also has the right under the agreement to make use of, develop, and offer for sale worldwide products containing Botulinum Toxin Type B. The agreement may not be terminated for convenience.
The company has a contract manufacturing agreement with Merz Pharma GmbH & Co. KGaA (Merz) for the manufacture and supply of MYOBLOC (Merz Agreement). Pursuant to the Merz Agreement, Merz is required to provide a dedicated manufacturing facility, including a stand-alone building, dedicated clean room suites, dedicated manufacturing and purification equipment, and filling and packaging production lines (collectively referred to as the manufacturing facility) to manufacture finished products. The Merz Agreement will expire in July 2027, unless the company and Merz mutually agree to extend the term.
SPN-817 (huperzine A)
In September 2018, the company entered into a merger agreement to acquire Biscayne Neurotherapeutics (Biscayne), a privately held company developing a novel treatment for epilepsy (SPN-817). Through this agreement, the company obtained worldwide rights, excluding certain markets in Asia where rights have been previously out-licensed, to SPN-817. SPN-817 has received Orphan Drug Designation from the FDA for the treatment of Dravet Syndrome, a severe form of childhood epilepsy, and Lennox-Gastaut Syndrome.
SPN-820 (NV-5138)
In April 2020, the company entered into a development agreement (the Development Agreement) with Navitor Inc. The company can terminate the Development Agreement upon 30 days' notice. Under the terms of the Development Agreement, the company and Navitor Inc. will jointly conduct a Phase 2 clinical program for NV-5138 (SPN-820) for treatment-resistant depression.
Namzaric
Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type is marketed by Allergan plc under an exclusive license agreement between Adamas Pharmaceuticals and Forest Laboratories Holdings Limited (Forest), an indirect, wholly-owned subsidiary of Allergan plc (collectively, Allergan) in the United States. Adamas Pharmaceuticals receives royalties on net sales of Namzaric from May 2020. Allergan is responsible for all manufacturing related to Namzaric.
In November 2012, Allergan was granted an exclusive license, with right to sublicense, certain of Adamas Pharmaceuticals' intellectual property rights relating to human therapeutics containing memantine in the United States. In connection with these rights, Allergan markets and sells Namzaric (memantine and donepezil hydrochlorides) extended-release capsules and NAMENDA XR (memantine hydrochloride) extended-release capsules for the treatment of moderate to severe dementia related to Alzheimer's disease.
License Agreements with Other Third Parties
The company has granted other companies, including United Therapeutics Corporation and Takeda Pharmaceuticals Company Ltd., rights to utilize certain of its proprietary technologies in the development of certain of their products. These technologies were used by these companies to develop certain other products, including Orenitram (treprostinil) and Mydayis. The company receives royalties under these arrangements based on net product sales of certain products developed using the licensed technologies.
The company has also entered into settlement and licensing agreements with generic companies to settle patent litigation and to grant non-exclusive licenses to market generic versions of Oxtellar XR and Trokendi XR in the U.S. Under certain licensing arrangements, the company is eligible to receive royalties based on net product sales as defined in the agreements, and the number of generic equivalent products on the market in the U.S. the company currently receive royalties from third parties related to certain agreements for Trokendi XR and Oxtellar XR.
Government Regulation
The U.S. Foreign Corrupt Practices Act (FCPA), to which the company is also subject, prohibits corporations and individuals from engaging in certain activities to obtain or retain business or influence a person working in an official capacity.
In order to be eligible to have the company's products paid for with federal funds under the Medicaid and Medicare Part B programs and purchased by certain federal agencies and grantees, the company must comply with the Veterans Health Care Act of 1992 (VHCA).
History
Supernus Pharmaceuticals, Inc. was founded in 2005. The company was incorporated in Delaware in 2005.
